The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Amgen

  • AMGN
  • NASDAQ
  • Consumer Products
  • Latest 144.09
  • Currency US$
  • Change 6.58
  • Percent Change 4.785 %
  • Volume 85
  • Tue Oct 21, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 138.49
  • Previous Close 137.51
  • High 145.49
  • Low 137.01
  • Bidx1 143.83
  • Askx1 144.92
  • 52-week High10/21 145.49
  • 52-week Low04/28 108.20
  • Beta 0.326
  • Market Cap 109,079.01M
  • EPS 7.99
  • P/E 18.034
  • Forward P/E 16.21
  • PEG 2.29
  • Annual Dividend 2.44
  • Yield 1.693

News

Financials & Calendars

Income Statement

  • Sales $18,959,000,000
  • Earnings $4,720,000,000
  • Return on Equity 21.05%

Cash Flow

  • Cash Flow --
  • Cash $3,687,000,000
  • Current Ratio 3.45

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $67,004,000,000
  • Liabilities $44,263,000,000
  • Liabilities-to-Equity Ratio 1.95

Price Ratios

  • Price to Sales 5.75
  • Price to Book 4.80
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings Jul 29 $1.99 Oct 27 $2.06
Surprises Jul 29 19.10% n/a n/a
Dividends Aug 12 $0.61 n/a n/a
Splits n/a -- n/a n/a

12 months ended Oct 22, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Related Securities
Symbol Type Latest % Chg

Officers

  • Robert A. Bradway Chairman of the Board; C.E.O.
  • Michael A. Kelly Acting Chief Financial Officer
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA
91320

Phone: (805)-447-1000
Fax: (805)-4471010

investor.relations@amgen.com
www.amgen.com

Ideas & Discussion

Live Discussion of AMGN on StockTwits
The Globe and Mail has
updated our Company Pages
Switch to the newly designed Company Pages format today for a more in-depth look at the companies you're following and pages that are easier to navigate. If you prefer the old layout after trying the new Company Pages, you can switch back anytime.